Vor Biopharma (VOR) Income towards Parent Company (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Income towards Parent Company data on file, last reported at -$31.3 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 8.31% year-over-year to -$31.3 million in Q1 2026; TTM through Mar 2026 was -$375.0 million, a 203.16% decrease from a year earlier, with the FY2025 full-year figure at -$598.5 million, down 133.68% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$31.3 million, up from -$33.3 million in the prior quarter.
• Over the last five years, Income towards Parent Company for VOR reached as high as -$23.0 million in Q2 2022 and fell as low as -$283.9 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$44.2 million across 5 years, with a median of -$30.0 million in 2023.
• Across the five-year window, Income towards Parent Company jumped 89.35% in 2022 and tumbled 917.39% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$26.6 million in 2022, then dropped by 7.62% to -$28.7 million in 2023, then declined by 13.05% to -$32.4 million in 2024, then dropped by 2.71% to -$33.3 million in 2025, then gained by 5.83% to -$31.3 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$31.3 million in Q1 2026, -$33.3 million in Q4 2025, and -$26.4 million in Q3 2025.